Axsome Therapeutics, Inc.
AXSM Healthcare Biotechnology
Axsome Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $638.5 million, up 65.5% from fiscal 2024. In the quarter to June 2026, revenue grew 45.5%, EPS fell 2.06%, free cash flow fell 2.98% and total debt rose 4.66%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
Follow AXSM
Axsome Therapeutics, Inc. (AXSM) EV/Sales
As of 16 October 2026, Axsome Therapeutics, Inc. (AXSM) trades at a EV/Sales of 10.2×. Over the past ten years it has ranged from 0.0× (March 2023) to 26.5× (June 2023); the current reading is higher than 69% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 13.9× | 36.82% |
| FY2024 | 10.2× | (16.42%) |
| FY2023 | 12.2× | — |
| FY2022 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 16.1× | 34.41% |
| Mar 2026 | 12.0× | (14.03%) |
| Dec 2025 | 13.9× | 33.00% |
| Sep 2025 | 10.5× | 4.01% |
| 13 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ABVX Abivax SA Sponsored ADR compare | n/m |
| CAI Caris Life Sciences,�Inc. compare | 8.3× |
| TGTX TG Therapeutics, Inc. compare | 9.8× |
| AXSM Axsome Therapeutics, Inc. | 10.2× |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | 10.9× |
| PTGX Protagonist Therapeutics, Inc. compare | 27.4× |
| KYMR Kymera Therapeutics, Inc. compare | 91.4× |
| CYTK Cytokinetics, Incorporated compare | 121× |
| SYRE Spyre Therapeutics, Inc. compare | 5,336× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)